

Key word index to volume 8

- Abnormal anaphase-telo-
phase cells, 529
- Acetylsalicylic acid, 62
- Aclarubicin, 666
- Activated carbon, 666
- Acute lymphoblastic leukemia, 517
- Acquired resistance, 911
- Adjuvant breast, 376
- Adozelesin, 588
- Adult T cell leukemia, 329
- Advanced gastric cancer, 396
- Alkaline elution, 245
- Alkylating
agents, 34, 588, 845
drugs, 509
- All-*trans* retinoic acid, 522
- Amifostine, 174
- Anaemia, 949
- Analog II, 964
- Aneugenic effect, 529
- Angiogenesis, 238, 746, 859
inhibitors, 238, 746
- Animal experiments, 182, 894
- Anthracene, 245
- Anthracyclines, 610
- Anti-adherence therapy, 894
- Anti-gene, 113
- Antibiotics, 34, 413
- Anticancer agents, 231
- Anticancer drug, 964
- Anticancer drugs, 73
- Anticancer therapy, 829
- Antiemetic treatment, 225
- Antiestrogen, 603
- Antineoplastic, 34
- Antisense, 113
- Antitumor
activity, 88
mechanism, 482
- Apoptosis, 80, 797, 958, 1007
- Arabinomannan, 156
- ATP, 541, 756, 767
- 5-Aza-2'-deoxycytidine, 56, 358
- Azonafide, 245
- B16 melanoma, 156, 894
- Bacille Calmette-Guerin, 217
- BIACore, 336
- Bioavailability, 296
- Biochemical modulation, 454
- Biodistribution, 696
- Bioluminescence, 767
- Bleomycin, 859
- Blood platelets, 204
- Breast cancer, 911, 943, 964
carcinoma, 470
- Calcitriol, 988
- Calcium, 988
- Camptothecin, 671
- Cancer, 345, 369, 597, 727, 949
chemotherapy, 3
therapy, 113
vaccines, 217
- Carbohydrate antigens, 217
- Carboplatin, 432
- Carboquone, 778
- 256-carcinoma, 835
- Cardiac toxicity, 714
- CBDCA, 649
- CD4/CD8 ratio, 643
- CDDP, 853
- cdk, 623
- Cell
adherence, 894
adhesion, 702
cycle, 470, 623, 903
differentiation, 958
lines, 189
proliferation, 379
- Cervix
cancer, 657
uteri, 522
- Chemoprotection, 34, 174
- Chemosensitivity, 48, 541, 756, 903
- Chemosensitizer, 125, 141
- Chemotherapy, 107, 125, 376, 379, 436, 454, 541, 549, 582, 790, 823, 949, 1007
- Chemotherapy-induced
neutropenia, 597
- Childhood acute lymphoblastic leukemia, 662
- Chloroadenosine, 445
- 2-Chloro-2'-deoxyadenosine, 445
- 2-Chloro-2'-arabino-fluoro-2'-deoxyadenosine, 445
- CHO cells, 869
- Choroid, 756
- Chromosomal aberrations, 73
- Chronomodulation, 454
- Cisplatin compounds, 34
- Cisplatin, 204, 225, 323, 349, 391, 509, 784, 797, 943, 1000
- Clinical trial, 296
- Clonogenic assay, 358
- Co-expression, 189
- Colon carcinoma, 56
- Colorectal cancer, 3, 293, 454, 790
- Combination
chemotherapy, 231, 876
effect, 1000
- Continuous infusion, 379, 714, 763, 823
- CPT-11, 231
- Cyclin dependent kinase
inhibitor, 1007
- Cyclobutanedicarboxylate, 649
- Cyclooxygenase, 62
- Cyclophosphamide, 257, 376
- Cyclopropyl antiestrogens, 964
- Cyclosporin A, 141
- Cytostatics, 174
- Cytotoxic LH-RH analogs, 974
- Cytotoxicity, 92, 164, 269, 345, 489, 618
- D-Amino acid, 702
- Dehydrogenases, 988
- Delayed-type hypersensitivity reaction, 217
- Deoxycytidine kinase, 517
- Dextran sulfate, 894
- Dibutyryl cAMP, 618
- Disseminated, 107
- Distamycin, 845
- DNA, 811
binding, 336
methylation, 56
minor-groove binders, 588
topoisomerase, 413
- Docetaxel, 379
- Dose intensification, 549
- Doxorubicin, 199, 265
- [¹¹¹In]DPTA, 677
- Drug
carriers, 677, 835
distribution, 182
resistance, 26, 349, 413, 470, 869
therapy, 582
- E2F, 283
- Efficacy, 436
- EILDV, 702
- Emesis, 436
- Endothelial cells, 859
- Enloplatin, 649
(-)-epigallocatechin, 265
(-)-epigallocatechin gallate, 265
- Epirubicin, 937, 943
- Epoetin α , 949
- Ergocalciferol, 988
- Eriochrome Black T, 746
- Estradiol resistance, 283
- Estrogen, 911
- Etoposide, 34, 164, 671
- Experimental breast cancer, 974
- Eye, 756
- Fibronectin, 702
- FKBP12, 125
- Flavone acetic acid, 778
- Flavonoids, 470
- Fluorescence spectroscopy, 67
- Fluorouracil, 376
- 5-Fluorouracil, 182, 257, 391, 396, 454, 1000
- 5-FU resistance, 293
- 5-Fluorouridine derivative, 482
- Folate-based thymidylate
synthase inhibitor, 3
- Folinic acid, 396
- Fostriecin, 413
- G-CSF, 204
- Gangliosides, 217
- Gastric cancer, 1000
- Gastrin, 853
- GD₂, 217
- GD₃, 217
- Gemcitabine, 574, 643
- GF120918, 141
- Glioma, 92
- Glutathione, 164, 199, 349

- peroxidase, 189
 S-transferase, 345, 349
 S-transferase- π 189
 GM-CSF, 269
 GM₂, 217
 Gonadotrophin releasing hormone, 369
 receptor, 369
 Granisetron, 225
 Granulocyte colony stimulating factor, 257, 657
 Green tea, 265
 Growth, 369, 756
 factors, 432
 inhibition, 283, 522
- Head and neck, 48
 cancer, 734
 Hematopoiesis, 466
 Hematopoietic growth factors, 549
 toxicity, 358
 Hepatocellular carcinoma, 500, 886
 Hepatoma, 898
 Homo-aza-steroidal esters, 73
 Human
 endothelial cells, 238
 leukemia, 767
 tumor xenografts, 845
 7-Hydroxymethotrexate, 119
 Hyperthermia, 778
 Hypoxic radiosensitizer, 386
- i.p.* chemotherapy, 182
 ICRF-193, 637
 Idarubicin, 42, 937
 IgG antibodies, 217
 Imaging agent, 386
 Immunocytochemistry, 662
 Immunohistochemistry, 931
 Immunotherapy, 156
in vitro, 231, 323, 541, 784
 cytotoxicity, 610
 studies, 671
In vivo efficacy, 696
 Indole, 489
 Infections, 597, 643
 Infusion, 42
 Inhibitors, 296
 iNOS, 853
 Intercalation, 245
 Interferon- α , 522
 Interferon- γ , 797
 Interleukin-1 α , 323, 784
 Interleukin-3, 288
 Intraleural paclitaxel, 565
 Irinotecan, 313
 Isobologram, 92
- analysis, 671
 Itasetron, 436
- Kinetics, 336
 Kupffer cell, 269
 KW-2149, 859
- Leukemia, 42
 Levofolinic acid, 257
 LH-RH receptors, 974
 Lipases, 988
 Lipid A, 500, 886, 898
 Lipo-polysaccharide, 500, 618
 Liver, 269
 Lobaplatin, 391
 Lonidamine, 943
 Low dose 1-hydroxyvitamin D₃, 466
 Low neuro-toxicity, 386
 LPS, 898
 LRP, 931
 Luminescence, 541
 Lung cancer, 231, 276, 358, 734
 Lung resistance-related protein, 662
 Lymphocytes, 643
 Lymphoma, 419
 Lysosomes, 323, 784
- M6, 466
 Macromolecular synthesis, 482
 Macrophages, 323, 784, 797
 Malignant lymphoma, 937
 melanoma, 1007
 pleural effusions, 565
 MCF-7, 964
 MCF-7, 283
 MDA-MB-231, 283, 964
 MDR modulator, 125
 MDR, 869
MDR1 gene product, 125
 Mechanism of action, 811
 Medroxyprogesterone acetate, 459
 Melanoma, 217, 756
 Melphalan, 509
 Mesoionic compounds, 88
 Metabolism, 419
 Methotrexate, 119, 677, 767
 Methotrexate-pharmacology, 835
 Micellar paclitaxel, 696
 Microspheres, 182
 Migration, 702
 Minimal residual disease, 269
 Mitomycin C, 859
 Mitoxantrone, 257, 376
- Mn-porphyrin, 386
 Modulation, 265
 Mono Mac 6 cells, 618
 mRNA, 517
 MS-209, 141
 Multicellular tumor spheroid, 48
 Multicenter, 574
 Multidrug resistance, 17, 199, 400, 610, 708
 Multidrug resistance-associated protein, 17, 141
 Murine tumors, 80
 Myelotoxicity, 845
- Neoadjuvant chemotherapy, 734
 Neoplasm, 376
 Nephrotoxicity, 988
 Neuroblastoma, 34, 174, 313, 958
 NF- κ B, 62
 NO, 853
 Non-Hodgkin's lymphoma, 937
 Non-small cell lung carcinoma, 582, 931
 NSCLC, 574
 Nucleoside analog, 574
 transport, 623
 Nude mice, 790
- O⁶-benzylguanine, 92
 OAW42, 509
 OAW42MER, 509
 Olomoucine, 623, 1007
 Ondansetron, 436
 ONO-4007, 886
 Oral
 administration, 296
 chemotherapy, 419
 mucositis, 119
 Ornithine deoxycarboxylase, 470
 Orthotopic models, 276
 Ovarian
 cancer, 432, 649, 763
 carcinoma, 189
 Oxygen radicals, 859
- P-glycoprotein, 141, 189, 199, 400, 708, 869
 Paclitaxel, 80, 396, 657, 714, 763, 823
 Pancreatic islets, 853
 Pancreatic cancer, 686
 Panomifene, 603
 Patient preference, 225
 Peptide nucleic acid, 113
 Peritoneal metastasis, 894
 Pharmacodynamics, 419
 Pharmacokinetic interac-
- tion, 400
 Pharmacokinetics, 42, 296, 358, 565, 603, 649, 677, 829, 835
 Pharmacology, 677
 Phase
 I, 588, 829, 454
 I/a, 603
 II, 293, 396, 574
 Phorbol-12-myristate-13-acetate, 618
 Phospholipase, 829
 Phosphoprotein phosphatases, 413
 Photofrin[®], 329
 Photosensitization, 164
 Platinum, 876, 949
 PNA, 113
 Polyglutamation, 3
 'Poly-plat', 323
 Porfimer sodium, 329
 pRb, 623
 Prediction, 541
 Prognostic value, 662
 Proliferation, 931
 Protein
 binding, 400
 kinase C, 26, 189
 synthesis, 73, 296
 Proto-oncogenes, 189
 Pulmonary
 metastasis, 156
 toxicity, 859
- Quality of life, 459
 Quinazoline antifolate, 876
- Radiotherapy, 92
 Randomized study, 459
ras transformation, 62
 Rat hepatoma cell, 199
 Receptor, 369
 Regulatory genes, 903
 Residual disease, 107
 Residualizing labels, 677, 835
 Resistance mechanisms, 3
 Retinoic acid receptor β , 56
 Retinoic acid, 56
 Reverse-phase HPLC, 445
 rhGM-CSF, 597
 Rhodamine 123, 869
 Rimino-phenazines, 708
 RT-PCR, 517
- S 16020-2, 276
 Safety, 436
 Saliva, 119
 SAP, 323
 Sarcoma, 823
 Scavenger receptors, 677
 Scintigraphy, 677, 835
 SDZ PSC 833, 400

Key word index to volume 8

- Seminoma, 107
- Sialyl
 - Lewis^a, 217
 - Lewis^x, 217
- Side effects, 174, 376
- Sister chromatid exchange, 637
- Skin tumors, 67
- Small cell lung cancer, 549
- Smoking, 931
- Snake venom, 829
- Sodium valproate, 958
- Soft agar cloning, 345
- Solid tumor, 459, 643
- Somatostatin, 853
- Sonodynamic therapy, 329
- Sparsomycin, 349
- Spindle poison, 529
- Squamous cell
 - cancer, 522
 - carcinoma, 48
- SSP, 323
- Stability, 445
- Stomach, 853
 - bloating, 988
- Storage, 445
- Strand breaks, 245
- Suramin, 746
- Surface plasmon resonance, 336
- Synergism, 164
- Synthesis, 88
- Tachycardia, 714
- Tamoxifen, 911
 - analog, 603,
- Targeted cancer therapy, 974
- Taxanes, 379, 714
- Taxol, 48, 784, 823, 853
- Temozolomide, 92
- TER286, 345
- Tetrahydrofolate, 632
- T_h2 cells, 156
- Therapeutic ultrasound, 329
- Thiazole, 489
- Thrombocytopenia, 288
- Thymidylate synthase, 189, 632
- TNF- α 898
- Topoisomerase, 811
 - I, 336
 - II, 276
 - II inhibitor, 637
 - inhibitors, 671
- Treated:control ratio of tumor weights, 632
- Trofosfamide, 293, 419
- Tumor
 - blood flow, 778
 - cells, 797
 - cells cultured, 34
 - growth, 26, 174
 - localizing agent, 386
 - metastasis, 702
 - necrosis factor, 80, 886
 - necrosis factor- α 323, 500, 784
 - promotion, 283
 - sensitivity assay, 767
 - normal skin ratio, 67
- Two-stage carcinogenesis, 67
- U937 cells, 618
- Ulceration, 853
- Vaccine, 727
- Verapamil, 141
- Vesnarinone, 686
- Vinca alkaloids, 34
- Vindesine, 734
- Vinorelbine, 529
- VP-16, 164
- VX-710, 141
- Walker,
 - Walker-256 carcino-sarcoma, 677
- White blood cells, 632
- WR-1065, 34
- WR-2721, 34
- Xenografts, 174, 276, 313
- Zilascorb(²H), 296